This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
Adults aged ≥18 years
Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
Patients prescribed with Xolair® as per the locally approved label information.
Patients who provide written informed consent to participate in the study
Patients who do not provide consent to participate in the study
Patients participating in other clinical trial
Contraindications listed in the locally approved label information of Xolair®
Hypersensitivity to the active ingredient or any other ingredient of Xolair®
Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)
Novartis Investigative Site
Bundang Gu,Gyeonggi Do,13620,Korea, Republic of